Format

Send to

Choose Destination
Metabolism. 2019 Mar;92:170-192. doi: 10.1016/j.metabol.2018.10.010. Epub 2018 Nov 1.

Pharmacotherapy of obesity: Available medications and drugs under investigation.

Author information

1
Division of Endocrinology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA 02215.
2
Division of Endocrinology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA 02215. Electronic address: ofarr@bidmc.harvard.edu.
3
First Department of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
4
Department of Medicine, Boston Medical Center, Boston, MA, 02118, United States of America.
5
Division of Pediatric Newborn Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, MA 02215, United States of America.
6
Division of Endocrinology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA 02215; Section of Endocrinology, VA Boston Healthcare System, Harvard Medical School, Boston, MA, USA.

Abstract

Obesity is a chronic disease with a continuously rising prevalence that currently affects more than half a billion people worldwide. Energy balance and appetite are highly regulated via central and peripheral mechanisms, and weight loss triggers a homeostatic response leading to weight regain. Lifestyle and behavioral modifications are the cornerstones of obesity management; however, they often fail to achieve or sustain long-term weight loss. Pharmacotherapy added onto lifestyle modifications results in an additional, albeit limited, weight reduction. Regardless, this weight reduction of 5-10% conveys multiple cardiovascular and metabolic benefits. In this review, evidence on the food and drug administration (FDA)-approved medications, i.e., orlistat, lorcaserin, phentermine/topiramate, liraglutide and naltrexone/bupropion, is summarized. Furthermore, anti-obesity agents in the pipeline for potential future therapeutic use are presented.

KEYWORDS:

Liraglutide; Lorcaserin; Naltrexone/bupropion; Obesity; Orlistat; Personalized therapy phentermine/topiramate

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center